

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock


Company

2024/04/17 22:00:00



Price
66.93
USD

Difference ▲
-0.56% (-0.38)



Contact Details

GILEAD SCIENCES INC. Tel: +1-650-574-3000
 -- Fax: +1-650-522-5853
 333 Lakeside Drive Web: <http://www.gilead.com>
 94404 Foster City E-mail: -

Company Profile

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Financial figures, Fiscal year: from 01.01. to 31.12.

Financial figures	2023		2022		2021	
	Assets	Liabilities and equity	Assets	Liabilities and equity	Assets	Liabilities and equity
Current assets	16,085,000,000		14,443,000,000		14,772,000,000	
Common stock capital		1,000,000		1,000,000		1,000,000
Fixed assets	46,040,000,000		48,728,000,000		53,180,000,000	
Equity capital of a company		22,749,000,000		21,209,000,000		21,064,000,000
Cash and cash equivalents	6,085,000,000		5,412,000,000		5,338,000,000	
Accrued liabilities		0		0		0
Other assets	-		-		-	
Current liabilities		11,280,000,000		11,237,000,000		11,610,000,000
Prepayments and accrued income	-		-		-	
Non-current liabilities		28,096,000,000		30,725,000,000		35,278,000,000
Different income		-		-		-
Other liabilities		2,773,000,000		5,095,000,000		5,254,000,000
Total assets	62,125,000,000	62,125,000,000	63,171,000,000	63,171,000,000	67,952,000,000	67,952,000,000

Balance notes

	2023	2022	2021
Accounting standard	US-GAAP	US-GAAP	US-GAAP
Employees	18,000	17,000	14,400
Equity ratio	36.48%	33.52%	30.99%
Debt-equity ratio	174.10%	198.29%	222.67%

Others

	2023	2022	2021
Tax Expense Rate	18.18%	21.47%	25.09%

GILEAD SCIENCES INC.

ISIN: US3755581036 WKN: 375558103 Asset Class: Stock

Income statement

	2023	2022	2021
Turnover	27,058,000,000	27,085,000,000	27,372,000,000
Net income	5,664,000,000	4,592,000,000	6,225,000,000
EBIT	6,976,181,100	6,339,335,700	8,715,764,700
Operating income before taxes	6,859,000,000	5,814,000,000	8,278,000,000
Cash Flow	8,006,000,000	9,072,000,000	11,384,000,000
Net interest income	-568,000,000	-935,000,000	-1,001,000,000
Research and development expenses	5,758,000,000	4,998,000,000	5,363,000,000
Income taxes	1,247,000,000	1,248,000,000	2,077,000,000
Result from investments in subsidiaries, associates and other	0	0	0
Revenues per employee	1,411,977	1,496,526	1,785,453

Board of Directors

Members of Management Board

Jacqueline Barton	Member of Board of Directors
Jeffrey Bluestone	Member of Board of Directors
Sandra Horning	Member of Board of Directors
Ted Love	Member of Board of Directors
Anthony Welters	Member of Board of Directors
Harish M. Manwani	Member of Board of Directors
Javier Rodriguez	Member of Board of Directors
Kelly Kramer	Member of Board of Directors
Kevin Lofton	Member of Board of Directors
Daniel O'Day	Chairman of Managing Board
Andrew Dickinson	Member of Executive Committee
Deborah H. Telman	Member of Executive Committee
Flavius Martin	Member of Executive Committee
Johanna Mercier	Member of Executive Committee
Jyoti Mehra	Member of Executive Committee
MD, PhD Merdad Parsey	Member of Executive Committee
Stacey Ma	Member of Executive Committee